173 related articles for article (PubMed ID: 7527291)
1. The pancreatitis-associated protein (PAP). A new candidate for neonatal screening of cystic fibrosis.
Iovanna JL; Férec C; Sarles J; Dagorn JC
C R Acad Sci III; 1994 Jun; 317(6):561-4. PubMed ID: 7527291
[TBL] [Abstract][Full Text] [Related]
2. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
[TBL] [Abstract][Full Text] [Related]
3. Positive neonatal screening for cystic fibrosis in neonates with renal failure.
Oosterveld MJ; Schilperoort JV; Lilien MR; Arets HG
Thorax; 2010 Jul; 65(7):652-3. PubMed ID: 20627926
[TBL] [Abstract][Full Text] [Related]
4. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study.
Vernooij-van Langen AM; Loeber JG; Elvers B; Triepels RH; Gille JJ; Van der Ploeg CP; Reijntjens S; Dompeling E; Dankert-Roelse JE;
Thorax; 2012 Apr; 67(4):289-95. PubMed ID: 22271776
[TBL] [Abstract][Full Text] [Related]
5. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations.
Sommerburg O; Krulisova V; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Votava F; Balascakova M; Skalicka V; Stopsack M; Gahr M; Macek M; Mall MA; Hoffmann GF
J Cyst Fibros; 2014 Jan; 13(1):15-23. PubMed ID: 23891278
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.
Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D
J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947
[TBL] [Abstract][Full Text] [Related]
7. [A new strategy of neonatal screening for cystic fibrosis. The association of immunoreactive trypsin and molecular biology in dried blood].
Laroche D; Peres O; Briard ML; Lemonnier F; Pasquet-Ferre C; Blandin C; Travert G; Fernandez Y
Arch Fr Pediatr; 1990 Apr; 47(4):251-3. PubMed ID: 2363611
[TBL] [Abstract][Full Text] [Related]
8. Does cystic fibrosis neonatal screening detect atypical CF forms? Extended genetic characterization and 4-year clinical follow-up.
Narzi L; Ferraguti G; Stamato A; Narzi F; Valentini SB; Lelli A; Delaroche I; Lucarelli M; Strom R; Quattrucci S
Clin Genet; 2007 Jul; 72(1):39-46. PubMed ID: 17594398
[TBL] [Abstract][Full Text] [Related]
9. A survey of newborn screening for cystic fibrosis in Europe.
Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
[TBL] [Abstract][Full Text] [Related]
10. Neonatal screening for cystic fibrosis: comparing the performances of IRT/DNA and IRT/PAP.
Sarles J; Giorgi R; Berthézène P; Munck A; Cheillan D; Dagorn JC; Roussey M
J Cyst Fibros; 2014 Jul; 13(4):384-90. PubMed ID: 24513262
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
Barthellemy S; Maurin N; Roussey M; Férec C; Murolo S; Berthézène P; Iovanna JL; Dagorn JC; Sarles J
Arch Pediatr; 2001 Mar; 8(3):275-81. PubMed ID: 11270251
[TBL] [Abstract][Full Text] [Related]
12. Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis.
Sarles J; Barthellemy S; Férec C; Iovanna J; Roussey M; Farriaux JP; Toutain A; Berthelot J; Maurin N; Codet JP; Berthézène P; Dagorn JC
Arch Dis Child Fetal Neonatal Ed; 1999 Mar; 80(2):F118-22. PubMed ID: 10325788
[TBL] [Abstract][Full Text] [Related]
13. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.
Sommerburg O; Lindner M; Muckenthaler M; Kohlmueller D; Leible S; Feneberg R; Kulozik AE; Mall MA; Hoffmann GF
J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932
[TBL] [Abstract][Full Text] [Related]
14. [Screening of newborn infants for cystic fibrosis. A combined analysis of immunoreactive trypsin and delta F508 mutation--a screening without false positive results].
Nørgaard-Pedersen B; Høgdall EV; Arends J; Vuust J
Ugeskr Laeger; 1994 Jun; 156(25):3757-60. PubMed ID: 8059453
[TBL] [Abstract][Full Text] [Related]
15. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA.
Krulišová V; Balaščaková M; Skalická V; Piskáčková T; Holubová A; Paděrová J; Křenková P; Dvořáková L; Zemková D; Kračmar P; Chovancová B; Vávrová V; Stambergová A; Votava F; Macek M
Eur J Pediatr; 2012 Aug; 171(8):1223-9. PubMed ID: 22581207
[TBL] [Abstract][Full Text] [Related]
16. Screening for cystic fibrosis in dried blood spots of newborns.
Audrézet MP; Costes B; Ghanem N; Fanen P; Verlingue C; Morin JF; Mercier B; Goossens M; Férec C
Mol Cell Probes; 1993 Dec; 7(6):497-502. PubMed ID: 8145780
[TBL] [Abstract][Full Text] [Related]
17. PAP assays in newborn screening for cystic fibrosis: a population-based cost-effectiveness study.
Seror V; Cao C; Roussey M; Giorgi R
J Med Screen; 2016 Jun; 23(2):62-9. PubMed ID: 26304152
[TBL] [Abstract][Full Text] [Related]
18. [Mucoviscidosis screening with immunoreactive trypsin].
Eber E; Ellemunter H; Engele H; Götz M; Grünberger W; Haas J; Janisch H; Leodolter S; Litscher H; Müller G
Wien Klin Wochenschr; 1992; 104(22):681-5. PubMed ID: 1475973
[TBL] [Abstract][Full Text] [Related]
19. The CF-CIRC study: a French collaborative study to assess the accuracy of cystic fibrosis diagnosis in neonatal screening.
Sermet-Gaudelus I; Roussel D; Bui S; Deneuville E; Huet F; Reix P; Bellon G; Lenoir G; Edelman A
BMC Pediatr; 2006 Oct; 6():25. PubMed ID: 17018149
[TBL] [Abstract][Full Text] [Related]
20. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF
Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]